Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 6/20 | 0.36 |
| ▸ | SELL | P14151 | 5/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294503 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL3781567 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL14957946 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL14332067 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL8013415 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL10534787 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL17001438 | 0.89 | TLR4 (0.34) | GPR84TLR4TBXA2RPTGFRPTGER2 | |
| SCHEMBL5055853 | 0.88 | SELL (0.41) | GPR84TLR4SELPSELL | |
| SCHEMBL8026363 | 0.88 | SELL (0.41) | GPR84TLR4SELPSELL | |
| SCHEMBL9129668 | 0.83 | GPR84 (0.33) | GPR84DAGLATBXA2RPTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108587995-B | Cells and methods for producing rhamnolipids | 赢创运营有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-2723348-B1 | METHOD FOR TREATING OBESITY | LEIGHTON ANTON (US) | 2019-08-14 | — | — | EP | claimed |
| US-20130310330-A1 | METHOD FOR TREATING OBESITY | LEIGHTON, ANTON | 2013-11-21 | — | — | US | claimed |
| CN-116710543-B | Cleaning composition | 联合利华知识产权控股有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4204505-B1 | POLISHING COMPOSITIONS AND METHODS OF USING THE SAME | FUJIFILM ELECTRONIC MAT USA INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4263773-B1 | CLEANING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| CN-114958684-B | Method for improving competent cell conversion rate | 上海龙殷生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240117270-A1 | CLEANING COMPOSITIONS AND METHODS OF USE THEREOF | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2024-04-11 | — | — | US | disclosed |
| CN-117858937-A | Concentrated cleaning composition | 联合利华知识产权控股有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117795046-A | Sanitary composition for reducing peculiar smell | 联合利华知识产权控股有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117795047-A | Sanitary composition for reducing odor | 联合利华知识产权控股有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20130296461-A1 | AQUEOUS COATINGS AND PAINTS INCORPORATING ONE OR MORE ANTIMICROBIAL BIOSURFACTANTS AND METHODS FOR USING SAME | RHODIA OPERATIONS (FR) | 2013-11-07 | — | — | US | disclosed |
| EP-2410039-A1 | Rhamnolipids with improved cleaning | Unilever PLC (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110257115-A1 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS | LEIGHTON, ANTON | 2011-10-20 | — | — | US | disclosed |
| EP-0920517-B1 | DNA SEQUENCE USEFUL FOR THE PRODUCTION OF POLYHYDROXYALKANOATES | METABOLIX INC (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010080406-A1 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS | ADREM BIOTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-RE37543-E1 | CLONED BY PHENOTYPE COMPLEMENTATION OF PSEUDOMONAS PUTIDA KT2440 MUTANTS, DEFECTIVE IN THE POLYHYDROXYALKANOIC ACID (PHA) SYNTHESIS VIA DE NOVO FATTY ACID BIOSYNTHESIS BUT NOT AFFECTED IN PHA BIOSYNTHESIS VIA FATTY ACID B-OXIDATION | MONSANTO COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0920517-A1 | DNA SEQUENCE USEFUL FOR THE PRODUCTION OF POLYHYDROXYALKANOATES | MONSANTO COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5750848-A | DNA sequence useful for the production of polyhydroxyalkanoates | MONSANTO COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1998006854-A1 | DNA SEQUENCE USEFUL FOR THE PRODUCTION OF POLYHYDROXYALKANOATES | MONSANTO COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257115-A1 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS | CMA1, HRH2, LIPA | GPR84 333/4885TLR4 1221/4885DAGLA 331/4885 |
| US-20130310330-A1 | METHOD FOR TREATING OBESITY | FABP4, LIPA, LIPC | GPR84 442/4885TLR4 1216/4885DAGLA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.